Author: admin

Empowering Future Innovators: Lattice Labs CEO Bijan Burnard Unveils Groundbreaking Blockchain Masterclass for Teens

In a bold and forward-thinking move, CEO Bijan Burnard of Lattice Labs, a global leader in blockchain development, recently announced an unprecedented opportunity for young minds. Lattice Labs is set to provide a free blockchain development and implementation masterclass to 2500 teenagers under the age of 18, inviting them to delve into the intricate world of blockchain technology.

The masterclass, a pioneering initiative in the realm of education and technology, aims to equip young talents with the skills and knowledge needed to navigate the dynamic landscape of blockchain development. Attendees will not only gain a comprehensive understanding of blockchain but will also receive a prestigious Lattice Labs blockchain Expert certificate, validating their newfound expertise.

What sets this program apart is the unique chance it offers participants to step into the professional arena through internships. Lattice Labs has collaborated with some of the world’s top luxury retail brands and global professional sports teams, where successful masterclass attendees will have the opportunity to experience firsthand the transformative power of blockchain within these renowned industries.

CEO Bijan Burnard expressed his enthusiasm for nurturing the next generation of blockchain innovators. “We believe in the potential of young minds to shape the future of technology. This masterclass is not just about education; it’s about providing real-world experiences that will set the stage for these teenagers to become leaders in the blockchain space,” Burnard stated.

The masterclass, scheduled between the 10th of February and the 10th of March, offers flexibility by allowing participants to choose between online sessions through an invited Lattice Labs link or physical attendance in five European capital cities. The physical classes will be led by Bijan Burnard himself alongside a team of seasoned blockchain experts.

This initiative not only reflects Lattice Labs’ commitment to innovation but also highlights their dedication to fostering diversity within the blockchain industry. By reaching out to teenagers, Lattice Labs is ensuring that the future of technology is shaped by a diverse and inclusive group of individuals.

As the world continues to witness the transformative impact of blockchain technology, initiatives like the Lattice Labs masterclass serve as a beacon of hope for aspiring young minds eager to contribute to the ever-evolving landscape of global innovation. With this visionary move, CEO Bijan Burnard and Lattice Labs are not just offering education; they are opening doors to a world of possibilities for the blockchain pioneers of tomorrow.

This groundbreaking masterclass signifies a broader shift in the tech industry’s approach to education and talent development. Lattice Labs’ commitment to providing tangible opportunities for young individuals to engage with cutting-edge technologies aligns with a growing recognition of the importance of early exposure to foster innovation.

The comprehensive curriculum of the masterclass covers a spectrum of blockchain development topics, from the fundamentals to advanced applications. Participants can expect hands-on experience, practical insights, and mentorship from industry experts, preparing them for the challenges and opportunities within the blockchain sector.

For more information, please visit https://latticelabs.io/

Media Contact
Company Name: Lattice Labs
Contact Person: Media Relations
Email: Send Email
Country: Morocco
Website: https://latticelabs.io/

Advanced Wildlife Removal Provides Solutions For Critter Emergencies

For a dozen years, Advanced Wildlife Removal has helped Virginia residents and business owners remove unwanted wildlife and critters from properties. The company is proud of its record of customer service.

Advanced Wildlife Removal and Paul Smith are pleased to announce that it has been helping residents of Virginia remove nuisance wildlife from their homes and businesses for more than a dozen years. The company takes great pride in its customer service; its work is thorough, and the job is completed successfully. Advanced Wildlife Removal ensures the customer’s peace of mind is the top priority. The family-owned and locally operated animal and wildlife control company is based in the heart of Virginia. It is dedicated to resolving pest problems no matter how big, small, or furry.

The team of wildlife removal experts is equipped with the knowledge and tools to address nearly any pest disrupting the customer’s life. The professionals understand the discomfort and potential dangers that unwanted wildlife can bring to a property, so AWR offers a comprehensive range of services to ensure a pest-free environment for customers. Advanced Wildlife Removal specializes in a variety of services to meet specific needs, including trapping solutions to capture and relocate wildlife. The company provides general wildlife control along with strategies to manage and prevent wildlife issues.

The professionals are effective at deterring birds from nesting and roosting on the customer’s property. Targeted removal services also provide solutions for moles, foxes, possums, rats, mice, raccoons, rodents, snakes, squirrels, and bats. 

For potential customers, the company offers a no-obligation site visit and a comprehensive evaluation of any pest problems. AWR is recognized for its exceptional customer service, meticulous attention to detail, and commitment to the satisfaction of customers. The expert removal team is available around the clock to ensure an efficient and fast response to animal control needs. The experienced and trained technicians are well-versed in the latest wildlife control techniques and are committed to resolving pest issues effectively.

Additional details are available at https://advancedwildliferemoval.org/

A careful evaluation of the property is dedicated to reclaiming the home from pests. Once the problem has been identified and a removal plan devised, the skilled technicians will not only remove the unwelcome guests but also address the damage they have left behind. Homeowners can trust the expertise and dedication of the Spotsylvania, VA, animal and wildlife control specialists at Advanced Wildlife Removal to ensure that the home and property are pest-free once again.

Paul Smith explains, “At Advanced Wildlife Removal, we are not just about solving problems; we are about providing peace of mind. Let us help you reclaim your space and enjoy the comfort of your home without the worry of unwanted wildlife. Contact us today to learn more about our services and how we can assist you. We get the job done the first time and have experience with all types of animal removal in the state of Virginia.”

Do-it-yourself pest removal efforts can be grossly ineffective and can even be dangerous and hazardous to the health. It is unhealthy to have an infestation of many types of pests, so call in the professionals to do the removal safely and effectively. When you call us for pest removal, we understand you want a fast and effective solution. Our process is designed to deliver just that while prioritizing the safety of your home and family. We thoroughly inspect your property, looking for signs of pest activity. This information will help us develop a professional pest control plan tailored to specific needs.

About the Company: 

Advanced Wildlife Removal offers professional expertise to control a range of unwanted pests and wildlife intruders. Some services include the removal of mice, rats, moles, possums, raccoons, voles, foxes, bats, and birds. The family-owned business features local experts with full training.

Media Contact
Company Name: Advanced Wildlife Removal
Contact Person: Paul Smith
Email: Send Email
Phone: (540) 501-7729
City: Fredericksburg
State: VA
Country: United States
Website: https://advancedwildliferemoval.org/

Unlock the Magic of Dreams and Discover Adventure and Inspiration in “Dreamer Gabie: Flying Umbrella”

Unlock the Magic of Dreams and Discover Adventure and Inspiration in "Dreamer Gabie: Flying Umbrella"
“Dreamer Gabie: Flying Umbrella,” a new children’s book by Ievgeniia Iermolenko, invites young readers on a magical journey with protagonist Gabie and her flying umbrella. The story encourages children to embrace and share their dreams, fostering imagination and creativity.

Dive into the whimsical world of “Dreamer Gabie: Flying Umbrella,” the latest children’s book by the talented Ievgeniia Iermolenko. This enchanting storybook is crafted for children who love to embark on adventures through their imagination, just like the protagonist, Gabie.

When Gabie receives an umbrella as a gift from her mother, it’s not just any umbrella. It’s the start of an exciting journey, a flying vessel that takes her into a world where anything is possible. Readers are invited to join Gabie as she soars on her magical flying umbrella, exploring realms woven from her vibrant dreams and stories.

Author and illustrator, Ievgeniia Iermolenko, brings her unique flair for creativity to every page. Ievgeniia dedicates her talent to crafting illustrated books that ignite the imagination and sharpen the attention to detail of young readers. Her characters are not just figures in a story; they are invitations to explore, dream, and discover.

“Dreamer Gabie: Flying Umbrella” calls on all little dreamers to embrace their inner worlds. Whether you dream of space adventures, courageous acts on stage, or the boundless realms of your imagination, this book is a testament to the power of dreams. Ievgeniia encourages every reader to dream without limits, share their visions, and believe in the possibility of making them a reality.

Praised by parents and children alike, “Dreamer Gabie: Flying Umbrella” has already captured hearts. One Amazon customer, Smart, declares it “Great for 4 years old! My daughter loves unicorns, so this is her favorite book now. Easy to read, just long enough for a bedtime story. Definitely will recommend it!” Another, Alex, says, “My daughter enjoys this book! Love it!”

Join Gabie in her journey and discover where your dreams can take you. “Dreamer Gabie: Flying Umbrella” is available on Amazon and on the author’s website: DreamerGabie.com. Don’t miss this opportunity to explore, dream, and inspire with every turn of the page. “Dreamer Gabie: Flying Umbrella” is available for readers to enjoy in English, Ukrainian, and Russian.

About the Book

Join little Gabie on her whimsical adventure in “Dreamer Gabie: Flying Umbrella.” In this heartwarming tale, Gabie isn’t just any child; she’s a dreamer whose imagination knows no bounds. When her mother gifts her an ordinary umbrella, Gabie sees it as a magical flying vessel! With a dash of creativity and a sprinkle of courage, she embarks on an exhilarating journey through the skies. Perfect for every child who dreams of the stars and beyond, this story is about the freedom to dream and the joy of sharing those dreams.

About the Author

Ievgeniia Iermolenko is a visionary children’s book author and illustrator hailing from New Jersey, where she cultivates her stories amidst the joy and inspiration of her family life with her husband, two children, and a fluffy cat named Buddy. With a rich background in storytelling and a passion for bringing children’s imaginations to life, Ievgeniia has earned acclaim for her ability to weave tales that not only entertain but also educate and inspire young minds. Her artistic prowess and dedication to fostering creativity and attention to detail shine through in each page of her work. Ievgeniia’s books, known for their delightful characters and imaginative settings, have become a staple in the homes of families seeking stories that celebrate the wonder of childhood dreams and adventures.

Media Contact
Company Name: Bennett Media and Marketing
Contact Person: Ievgeniia Iermolenko
Email: Send Email
Country: United States
Website: https://www.dreamergabie.com/

DIDWW to showcase advanced Voice and SMS solutions at PTC’24

DIDWW, a global provider of high-quality VoIP communications, two-way SIP trunking and SMS services, is gearing up to participate in the Pacific Telecommunications Council’s Annual Conference 2024 (PTC’24). Recognized as a premier event in the Pacific Rim telecom industry, the show stands out as an important meeting point for global communication professionals, fostering an environment that encourages valuable insights and networking opportunities.

PTC’24 will take place from January 21-24 at the Hilton Hawaiian Village® Waikiki Beach Resort in Honolulu, Hawaii. Bringing together more than 5000 attendees from over 60 countries, PTC’s annual conference offers a four-day event dedicated to planning, networking, and exploring the future of the Information and Communications Technology (ICT) field. At this exhibition, DIDWW will showcase the latest advancements to its powerful two-way SIP trunking solution, A2P and P2P SMS, along with other innovative VoIP services. With years of experience in the telecom industry, DIDWW consistently provides reliable, scalable, and cost-effective alternatives to traditional telephone networks in over 80 countries around the globe.

Attendees at PTC’s Annual Conference are invited to engage with the DIDWW team. To arrange a dedicated session in advance, it is recommended to schedule a meeting by reaching out via email at sales@didww.com or by contacting their account manager.

Karolis Jurys, Commercial Director at DIDWW, said, “This event enables us to actively engage in industry discussions and influence the further development of communication technologies. Our goal is to have a meaningful and lasting impact on the future of communications in the Pacific Rim and beyond.”

About DIDWW

DIDWW is a platform for telecommunication professionals with full self-service access and real-time provisioning, APIs and all the necessary building blocks for achieving the ultimate control over Voice and SMS services.

The company offers the largest fully compliant international coverage of local, national, mobile, toll-free voice and SMS-enabled virtual phone numbers, two-way local and global SIP trunks, access to local emergency services, flexible capacity options, free global number portability, a highly scalable PBX platform, and more.

DIDWW delivers premium quality services to thousands of operators and enterprises worldwide through a private and fully geo-redundant network with mission-critical reliability and guaranteed SLAs. Their customers enjoy advanced solutions coupled with a unique service experience and superior value, all driven by a highly motivated team of professionals.

To learn more about DIDWW, please visit https://www.didww.com/.

Media Contact
Company Name: DIDWW
Contact Person: Vilija Simkiene
Email: Send Email
Phone: +1 (212) 461 1854
City: Dublin
Country: Ireland
Website: https://www.didww.com/

Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis | Latest FDA, EMA, and PMDA Approvals | Alexion Pharma, Apellis Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, RA Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Paroxysmal Nocturnal Hemoglobinuria pipeline constitutes 20+ key companies continuously working towards developing 25+ Paroxysmal Nocturnal Hemoglobinuria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Paroxysmal Nocturnal Hemoglobinuria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Paroxysmal Nocturnal Hemoglobinuria Market.

 

Some of the key takeaways from the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Paroxysmal Nocturnal Hemoglobinuria treatment therapies with a considerable amount of success over the years. 
  • Paroxysmal Nocturnal Hemoglobinuria companies working in the treatment market are Amyndas Pharmaceuticals, Arrowhead Pharmaceuticals, Kira Pharmaceuticals (US), LLC., Alexion AstraZeneca Rare Disease, Regeneron Pharmaceuticals, and others, are developing therapies for the Paroxysmal Nocturnal Hemoglobinuria treatment 
  • Emerging Paroxysmal Nocturnal Hemoglobinuria therapies in the different phases of clinical trials are- AMY 101, ARO-C3, KP104, Danicopan, Pozelimab, and others are expected to have a significant impact on the Paroxysmal Nocturnal Hemoglobinuria market in the coming years.   
  • In March 2023, Regeneron Pharmaceuticals has started a trial named “An Open-Label Extension Study for Assessing the Extended Safety, Tolerance, and Effectiveness of Pozelimab and Cemdisiran Combined Treatment in Individuals Affected by Paroxysmal Hemoglobinuria.” The main goal of this study is to outline the extended-term safety, tolerance, and effectiveness of the combined therapy involving Pozelimab and Cemdisiran in patients diagnosed with PNH. Presently, the trial is ongoing, involving 300 participants, and it’s expected to conclude by March 2028.
  • In August 2022, Regeneron Pharmaceuticals has begun a trial named “A Study Comparing Pozelimab and Cemdisiran Combined Therapy with a C5 Inhibitor in a Randomized, Open-Label Setting to Assess its Effectiveness and Safety in Patients Diagnosed with Paroxysmal Hemoglobinuria, who have not previously used complement inhibitor treatment or have not received such therapy recently.

 

Paroxysmal Nocturnal Hemoglobinuria Overview

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of the blood characterized by the premature destruction of red blood cells (hemolysis), blood clotting issues, and the potential development of blood clots (thrombosis). PNH arises due to a mutation in the bone marrow stem cells, leading to the deficiency or absence of certain proteins that help protect blood cells from the immune system’s attack.

 

Get a Free Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight

 

Emerging Paroxysmal Nocturnal Hemoglobinuria Drugs Under Different Phases of Clinical Development Include:

  • AMY 101: Amyndas Pharmaceuticals
  • ARO-C3: Arrowhead Pharmaceuticals
  • KP104: Kira Pharmaceuticals (US), LLC.
  • Danicopan: Alexion AstraZeneca Rare Disease
  • Pozelimab: Regeneron Pharmaceuticals

 

Paroxysmal Nocturnal Hemoglobinuria Route of Administration

Paroxysmal Nocturnal Hemoglobinuria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Paroxysmal Nocturnal Hemoglobinuria Molecule Type

Paroxysmal Nocturnal Hemoglobinuria Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics Assessment

  • Paroxysmal Nocturnal Hemoglobinuria Assessment by Product Type
  • Paroxysmal Nocturnal Hemoglobinuria By Stage and Product Type
  • Paroxysmal Nocturnal Hemoglobinuria Assessment by Route of Administration
  • Paroxysmal Nocturnal Hemoglobinuria By Stage and Route of Administration
  • Paroxysmal Nocturnal Hemoglobinuria Assessment by Molecule Type
  • Paroxysmal Nocturnal Hemoglobinuria by Stage and Molecule Type

 

DelveInsight’s Paroxysmal Nocturnal Hemoglobinuria Report covers around 25+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Paroxysmal Nocturnal Hemoglobinuria product details are provided in the report. Download the Paroxysmal Nocturnal Hemoglobinuria pipeline report to learn more about the emerging Paroxysmal Nocturnal Hemoglobinuria therapies

 

Some of the key companies in the Paroxysmal Nocturnal Hemoglobinuria Therapeutics Market include:

Key companies developing therapies for Paroxysmal Nocturnal Hemoglobinuria are – Alexion Pharmaceuticals, Apellis Pharmaceuticals, Hoffmann-La Roche, Novartis, Regeneron Pharmaceuticals, RA Pharmaceuticals Inc., and others.

 

Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis:

The Paroxysmal Nocturnal Hemoglobinuria pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Paroxysmal Nocturnal Hemoglobinuria with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Paroxysmal Nocturnal Hemoglobinuria Treatment.
  • Paroxysmal Nocturnal Hemoglobinuria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Paroxysmal Nocturnal Hemoglobinuria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Paroxysmal Nocturnal Hemoglobinuria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Paroxysmal Nocturnal Hemoglobinuria drugs and therapies

 

Paroxysmal Nocturnal Hemoglobinuria Pipeline Market Drivers

  • Treatment approach for Paroxysmal Hemoglobinuria is rapidly evolving, increasing adoption of novel therapeutics and rising geriatric population are some of the important factors that are fueling the Paroxysmal Nocturnal Hemoglobinuria Market.

 

Paroxysmal Nocturnal Hemoglobinuria Pipeline Market Barriers

  • However, high treatment cost, reimbursement Policies and other factors are creating obstacles in the Paroxysmal Nocturnal Hemoglobinuria Market growth.

 

Scope of Paroxysmal Nocturnal Hemoglobinuria Pipeline Drug Insight    

  • Coverage: Global
  • Key Paroxysmal Nocturnal Hemoglobinuria Companies: Amyndas Pharmaceuticals, Arrowhead Pharmaceuticals, Kira Pharmaceuticals (US), LLC., Alexion AstraZeneca Rare Disease, Regeneron Pharmaceuticals, and others
  • Key Paroxysmal Nocturnal Hemoglobinuria Therapies: AMY 101, ARO-C3, KP104, Danicopan, Pozelimab, and others
  • Paroxysmal Nocturnal Hemoglobinuria Therapeutic Assessment: Paroxysmal Nocturnal Hemoglobinuria current marketed and Paroxysmal Nocturnal Hemoglobinuria emerging therapies
  • Paroxysmal Nocturnal Hemoglobinuria Market Dynamics: Paroxysmal Nocturnal Hemoglobinuria market drivers and Paroxysmal Nocturnal Hemoglobinuria market barriers 

 

Request for Sample PDF Report for Paroxysmal Nocturnal Hemoglobinuria Pipeline Assessment and clinical trials

 

Table of Contents

1. Paroxysmal Nocturnal Hemoglobinuria Report Introduction

2. Paroxysmal Nocturnal Hemoglobinuria Executive Summary

3. Paroxysmal Nocturnal Hemoglobinuria Overview

4. Paroxysmal Nocturnal Hemoglobinuria- Analytical Perspective In-depth Commercial Assessment

5. Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapeutics

6. Paroxysmal Nocturnal Hemoglobinuria Late Stage Products (Phase II/III)

7. Paroxysmal Nocturnal Hemoglobinuria Mid Stage Products (Phase II)

8. Paroxysmal Nocturnal Hemoglobinuria Early Stage Products (Phase I)

9. Paroxysmal Nocturnal Hemoglobinuria Preclinical Stage Products

10. Paroxysmal Nocturnal Hemoglobinuria Therapeutics Assessment

11. Paroxysmal Nocturnal Hemoglobinuria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Paroxysmal Nocturnal Hemoglobinuria Key Companies

14. Paroxysmal Nocturnal Hemoglobinuria Key Products

15. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs

16 . Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers

17. Paroxysmal Nocturnal Hemoglobinuria Future Perspectives and Conclusion

18. Paroxysmal Nocturnal Hemoglobinuria Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis | Latest FDA, EMA, and PMDA Approvals | Alexion Pharma, Apellis Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, RA Pharma

Ecosense and RadonTec To Bring Innovative Radon Detection and Monitoring Solutions across Europe.

The partnership enhances the safety of homes and workplaces through implementing state-of-the-art technology.

San Jose, California – January 10, 2024 – Ecosense, a leading provider of breakthrough radon detection and monitoring solutions headquartered in California, United States, is delighted to announce a strategic partnership with RadonTec, a Germany-based company specializing in radon testing and measurement. This collaboration marks a significant step forward in the realm of radon detection and monitoring, with the shared goal of enhancing safety and well-being for homeowners and workplaces across Europe, particularly in Germany.

RadonTec, a family-run company, boasts over a decade of expertise in radon protection. Recognized as trained radon experts by the Bavarian Environment Agency in Germany since 2013, RadonTec brings a wealth of knowledge and experience to this partnership. Together, Ecosense and RadonTec aim to make meaningful contributions to the advancement of radon safety practices.

Ecosense has been ramping up its dedication to advancing radon detection technology worldwide, and o a Distribution Agreement with RadonTec is another significant step in Ecosense’s efforts to make cutting-edge radon monitors available globally. As part of this partnership, starting with RadonEye over the years and has gained popularity among RadonTec customers. All Ecosense consumer-focused products, including EcoQube and EcoBlu, are now accessible on the RadonTec Shop website, and professional-grade solutions such as  EcoTracker will also be available  in the near future this year. 

Insoo Park, the CEO of Ecosense, said, “This partnership represents a leap in Ecosense’s mission to create safer living environments. With our combined dedication to innovation and expertise, we are on track to revolutionizing radon detection throughout Europe and ensuring homes and workplaces are safe from radon dangers for everyone.”

Martin Waltl, the CEO and Executive Director of RadonTec, expressed his excitement about the partnership by saying, “We’re thrilled to team up with Ecosense to bring real-time radon detection and monitoring technology with the industry’s best radon sensitivity to our valued customers. This collaboration perfectly aligns with our dedication to offering top-notch solutions for radon-related concerns.”

Thanks to the combined expertise of Ecosense and RadonTec, homeowners and radon professionals in Europe can now access cutting-edge radon detection and monitoring solutions that promote living and working environments.

For details about RadonTec and their products, please visit their website at RadonTec.de

About Ecosense®

Based in the heart of Silicon Valley, Ecosense is a leader in and trusted provider of both professional and consumer radon detection and monitoring solutions that are easy to use, accurate, and fast. The company’s smart real-time radon detectors utilize a patented detection technology with high accuracy, delivering reliable results in minutes, not days. The EcoQube was named to TIME’s List of the 100 Best Inventions of 2021 and previously was recognized as a CES 2021 Innovation Awards Honoree in the health and wellness category. Ecosense’s patented ion chamber technology performance has received independent validation from the University of Michigan (Dept. of Nuclear Engineering and Radiological Science) and the Kansas State University Radon Chamber. Both studies concluded that Ecosense’s Patented Technology performed comparably to premium research-grade detectors. 

Additionally, the 2023 Canadian National Radon Proficiency Program (C-NRPP) study on the intercomparison of consumer continuous radon monitors positioned Ecosense as the forefront leader in accurate and precise radon detection within the industry.

About RadonTec

RadonTec is a company that focuses on providing radon protection solutions. With more than ten years of experience, RadonTec has become a trusted source for addressing radon-related concerns. Since 2013, the Bavarian Environment Agency has recognized them as trained radon experts. RadonTec has also earned recognition from the German Federal Office for Radiation Protection as an Accredited Body in accordance with §155 StrlSchV for radon testing and measurements in workplaces. RadonTec offers an array of services, including expert guidance on radon, planning, accurate measurements, and the implementation of preventive and remedial measures. RadonTec is committed to ensuring radon protection for its clients.

Media Contact
Company Name: OtterPR
Contact Person: Thomas Mustac
Email: Send Email
Address:320 1st Ave N
City: St. Petersburg
State: Florida
Country: United States
Website: OtterPR.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ecosense and RadonTec To Bring Innovative Radon Detection and Monitoring Solutions across Europe.

AV Access Unveils a Plug-and-Play 4K AV over IP Solution for Creating Video Walls in Sports Bars

“Nowadays, AV over IP solutions have become increasingly popular among audio/video project installers and integrators across the globe. AV Access’s brand-new 4K HDMI over IP encoder/decoder is plug-n-play and requires no configuration on Ethernet switches, perfect for sports bar, house of worship, retail, etc.”
The 4KIP200 4K HDMI over IP encoder & decoder is super easy to install and requires no configuration on the Ethernet switch. Users can build a video wall up to 8×8 within minutes just on their palms.

AV Access, a leading provider of Pro AV and AV over IP solutions, has recently introduced its brand-new 4KIP200 4K HDMI over IP solution. It is the upgraded version of HDIP100, AV Access’s best-selling product in the same category.

The HDMI over IP codecs can work flawlessly with an unmanaged Ethernet switch, so users don’t need to spend much time configuring a managed switch that they usually adopted before for AV over IP solutions. With its easy-to-use and plug-n-play features, 4KIP200 can be widely used in sports bar, shopping mall, house of worship, conference room, etc.

No Configuration Required, Truly Plug-n-Play Solution

The 4KIP200 AV over IP solution supports both unicast and multicast streaming, so it can easily work with universal managed and unmanaged Ethernet switches on the market. “Whether you are an installer or end-user, you can effortlessly complete installation, even if you were not exposed to any IP knowledge before,” explained Bill Liao, CTO of AV Access.

The 4KIP200 HDMI over IP solution supports one-to-one, one-to-many and many-to-many applications. One pair of hdmi encoder and decoder can work together to transmit 4K ultra HD HDMI signal up to 394ft/120m. Users can also add up to 254 units of encoders or decoders to form a distributed IP matrix, which is far more flexible and cost-effective than traditional matrixes.

Whether in a sports bar or house of worship, users can install it to meet their needs of AV extension, distribution, switching, video wall and mobile centralized control. It enables their patrons or parishes to enjoy the best screen viewing experience possible.

Video Wall Support & Visual Control

With the intuitive and user-friendly VDirector App installed on a mobile device, visual control on palms can be quite easy. Users can connect a wireless router to deliver data from the codecs to the mobile device via the Ethernet switch.

With just a few drag-and-drop steps, users can perform matrix switching, or build a video wall up to 8×8 with different layouts. In addition to iPhone, iPad, Android smartphone and tablet, users can also install the “VDirector” App on a Windows PC for visual management and control.

What’s more, this zero-configuration 4K AV over IP system supports audio de-embedding, RS232 pass-through, PoE and fast seamless switching.

“Now the host-selling 4KIP200 HDMI over IP encoder/decoder is only priced at $249.99 on our official site, with a 15% discount for our partners ($212.49). It’s time to upgrade the HDMI distribution system in your sports bar,” added Bill.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP products, which include extenders, splitters, switchers, matrixes, AV over IP codecs, etc. Since establishment, it has long been our mission to offer ultimate audiovisual experience to the masses by delivering quality-assured and well-designed AV products at honest pricing. We will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access be qualified as your faithful partner! Learn more by visiting www.avaccess.com

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Unveils a Plug-and-Play 4K AV over IP Solution for Creating Video Walls in Sports Bars

Chronic Spontaneous Urticaria Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, & Clinical Trials | GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Chronic Spontaneous Urticaria pipeline constitutes 20+ key companies continuously working towards developing 20+ Chronic Spontaneous Urticaria treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Spontaneous Urticaria Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Chronic Spontaneous Urticaria Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Spontaneous Urticaria Market.

 

Some of the key takeaways from the Chronic Spontaneous Urticaria Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Chronic Spontaneous Urticaria treatment therapies with a considerable amount of success over the years. 
  • Chronic Spontaneous Urticaria companies working in the treatment market are Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others, are developing therapies for the Chronic Spontaneous Urticaria treatment 
  • Emerging Chronic Spontaneous Urticaria therapies in the different phases of clinical trials are- YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others are expected to have a significant impact on the Chronic Spontaneous Urticaria market in the coming years.   
  • In August 2023, Novartis announced positive top-line results from the Phase III REMIX-1 and REMIX-2 studies evaluating remibrutinib 25 mg b.i.d., a Bruton’s tyrosine kinase (BTK) inhibitor, in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines. Both Phase III studies met their primary endpoint of absolute change from baseline in weekly urticaria activity score (UAS7) at Week 12,demonstrating clinically meaningful and statistically significant improvements in disease activity. The studies will continue until Week 52.
  • In December 2022, Novartis Pharmaceuticals has launched a study named “An Investigation by Multiple Centers, Employing a Double-blind, Placebo-controlled, Random Withdrawal Method, and Subsequent Open-label Extension Study, Followed by Extended Open-label Treatment Periods to Evaluate the Effectiveness, Safety, and Tolerance of Remibrutinib (LOU064) in Adult Patients Diagnosed with Chronic Spontaneous Urticaria who have Finished the Prior Remibrutinib Phase 3 Trials.”
  • In October 2022, According to a publication in The Journal of Allergy & Clinical Immunology, a study revealed that Remibrutinib showcased notable effectiveness in managing moderate to severe cases of chronic spontaneous urticaria (CSU), exhibiting a rapid onset of action and demonstrating a positive safety profile. This conclusion stemmed from a randomized, double-blind phase 2b study involving 311 participants aged 18 and above (with an average age of 45 years; 71.4% female) who had moderately or more severe ongoing CSU that wasn’t adequately controlled using second-generation H1-antihistamines.

 

Chronic Spontaneous Urticaria Overview

Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, is a persistent skin condition characterized by the recurrent appearance of hives (urticaria). These hives are red, raised, itchy welts or wheals that develop suddenly on the skin. When these hives occur for six weeks or more without any specific identifiable cause, it is termed as chronic.

 

Get a Free Sample PDF Report to know more about Chronic Spontaneous Urticaria Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-pipeline-insight

 

Emerging Chronic Spontaneous Urticaria Drugs Under Different Phases of Clinical Development Include:

  • YH35324: Yuhan Corporation
  • TLL018: Hangzhou Highlightll Pharmaceutical Co., Ltd
  • CDX-0159: Celldex Therapeutics
  • UB-221: United BioPharma
  • Tezepelumab: Amgen
  • CT-P39: Celltrion
  • LOU064: Novartis Pharmaceuticals

 

Chronic Spontaneous Urticaria Route of Administration

Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Chronic Spontaneous Urticaria Molecule Type

Chronic Spontaneous Urticaria Products have been categorized under various Molecule types, such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Chronic Spontaneous Urticaria Pipeline Therapeutics Assessment

  • Chronic Spontaneous Urticaria Assessment by Product Type
  • Chronic Spontaneous Urticaria By Stage and Product Type
  • Chronic Spontaneous Urticaria Assessment by Route of Administration
  • Chronic Spontaneous Urticaria By Stage and Route of Administration
  • Chronic Spontaneous Urticaria Assessment by Molecule Type
  • Chronic Spontaneous Urticaria by Stage and Molecule Type

 

DelveInsight’s Chronic Spontaneous Urticaria Report covers around 20+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Chronic Spontaneous Urticaria product details are provided in the report. Download the Chronic Spontaneous Urticaria pipeline report to learn more about the emerging Chronic Spontaneous Urticaria therapies

 

Some of the key companies in the Chronic Spontaneous Urticaria Therapeutics Market include:

Key companies developing therapies for Chronic Spontaneous Urticaria are – GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharmaceutical, Genentech, AstraZeneca, Kiniksa Pharmaceuticals, Ltd, United BioPharma, and others.

 

Chronic Spontaneous Urticaria Pipeline Analysis:

The Chronic Spontaneous Urticaria pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Spontaneous Urticaria with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria Treatment.
  • Chronic Spontaneous Urticaria key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Spontaneous Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Spontaneous Urticaria market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Chronic Spontaneous Urticaria drugs and therapies

 

Chronic Spontaneous Urticaria Pipeline Market Drivers

  • Increasing prevalence of Chronic Spontaneous Urticaria, development of Novel Treatments are some of the important factors that are fueling the Chronic Spontaneous Urticaria Market.

 

Chronic Spontaneous Urticaria Pipeline Market Barriers

  • However, difficulty in identifying the condition, lack of awareness about the treatment and other factors are creating obstacles in the Chronic Spontaneous Urticaria Market growth.

 

Scope of Chronic Spontaneous Urticaria Pipeline Drug Insight    

  • Coverage: Global
  • Key Chronic Spontaneous Urticaria Companies: Yuhan Corporation, Hangzhou Highlightll Pharmaceutical Co., Ltd, Celldex Therapeutics, United BioPharma, Amgen, Celltrion, Novartis, and others
  • Key Chronic Spontaneous Urticaria Therapies: YH35324, TLL018, CDX-0159, UB-221, Tezepelumab, CT-P39, LOU064, and others
  • Chronic Spontaneous Urticaria Therapeutic Assessment: Chronic Spontaneous Urticaria current marketed and Chronic Spontaneous Urticaria emerging therapies
  • Chronic Spontaneous Urticaria Market Dynamics: Chronic Spontaneous Urticaria market drivers and Chronic Spontaneous Urticaria market barriers 

 

Request for Sample PDF Report for Chronic Spontaneous Urticaria Pipeline Assessment and clinical trials

 

Table of Contents

1. Chronic Spontaneous Urticaria Report Introduction

2. Chronic Spontaneous Urticaria Executive Summary

3. Chronic Spontaneous Urticaria Overview

4. Chronic Spontaneous Urticaria- Analytical Perspective In-depth Commercial Assessment

5. Chronic Spontaneous Urticaria Pipeline Therapeutics

6. Chronic Spontaneous Urticaria Late Stage Products (Phase II/III)

7. Chronic Spontaneous Urticaria Mid Stage Products (Phase II)

8. Chronic Spontaneous Urticaria Early Stage Products (Phase I)

9. Chronic Spontaneous Urticaria Preclinical Stage Products

10. Chronic Spontaneous Urticaria Therapeutics Assessment

11. Chronic Spontaneous Urticaria Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Spontaneous Urticaria Key Companies

14. Chronic Spontaneous Urticaria Key Products

15. Chronic Spontaneous Urticaria Unmet Needs

16 . Chronic Spontaneous Urticaria Market Drivers and Barriers

17. Chronic Spontaneous Urticaria Future Perspectives and Conclusion

18. Chronic Spontaneous Urticaria Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Spontaneous Urticaria Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, & Clinical Trials | GlaxoSmithKline, Allakos, Eli Lilly and Company, Roche, Novartis, Sanofi Pharma

Leading Real Estate Agency In Morristown, New Jersey Discusses Why Home Prices Might Not Be A Surprise

Most people have champagne dreams of the value of a home when putting it onto the market. Buyers, on the other hand, want to find the least expensive home for their budget as possible. This is a very difficult balance to meet.

This is where the services of a leading real estate selling agent of Morristown, NJ like Adrienne Francis. Francis has been in the residential real estate industry for years and has helped plenty of clients buy and sell homes with as little stress as possible.

Francis sits down with each client and works with them individually, taking into account all of the needs and negotiables for buying and selling a home. She goes through the details that make a property sell and sell at a premium price.

“I go through things like how to come up with a price, how to prepare the home for showing, marketing and other information. We also discuss the inspection and the real details of budget, design and potential resale value,” continued Francis.

Francis is recognized as one of the top Realtor agents in Morristown, New Jersey, are always interested in helping a client find or sell a home. She promises quality service and laser focus on meeting the client needs.

Adrienne Francis is one of the top real estate agents in Morristown, NJ. She has helped clients buy and sell homes where others have fallen short. Visit the website at http://www.adriennefrancis.com to see listed homes and contact information.

Media Contact
Company Name: Adrienne Francis, COMPASS | Real Estate Agent In Morristown NJ
Contact Person: Adrienne Francis
Email: Send Email
Address:67 E Park Pl Suite 175
City: Morristown
State: NJ 07960
Country: United States
Website: https://adriennefrancis.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agency In Morristown, New Jersey Discusses Why Home Prices Might Not Be A Surprise

Durham, NC Real Estate Agent Drives Business Success in City’s Rapid Growth Phase

Steed Rollins, a top real estate agent in Durham, NC, has been instrumental in shaping the success of the real estate market amidst the city’s rapid growth. Since launching his career in 2014, Rollins has adeptly capitalized on Durham’s emergence as a key destination, both statewide and nationally.

Rollins attributes much of his business growth to Durham’s accelerated development. “The city’s expansion has created unique opportunities in the real estate sector, especially for both residential and commercial properties,” he explains. His expertise as a Realtor agent in Durham, NC, has been crucial in guiding clients through these dynamic market conditions.

As a full-service Realtor, Rollins excels in both listing and buying roles. His commitment to superior customer service, attention to client preferences, and robust negotiation skills have earned him a distinguished reputation. “My approach is deeply client-focused. I believe in providing personalized solutions that meet each client’s specific needs,” Rollins says, emphasizing his role as a real estate selling agent Durham, NC.

Rollins’ extensive local market knowledge is a significant asset. His lifelong residency in Durham and educational background, including an MBA from Duke University, have equipped him with unparalleled insights into the local real estate market. As a real estate listing agent in Durham, NC, he leverages these insights to benefit his clients, whether in pricing homes accurately or crafting competitive offers.

Steed Rollins stands out among Durham NC Realtors for his unwavering dedication to his clients and his commitment to excellence. “I invite anyone interested in the Durham real estate market to experience the professional service and local expertise my team and I offer,” Rollins concludes, encouraging potential clients to reach out for top-notch real estate guidance.

For more information, visit Steed Rollins’ website and discover the advantages of working with a leading Realtor in Durham, NC. Learn more at the website. Visit http://steedrollins.com/

Media Contact
Company Name: Steed Rollins Realtor | Real Estate Agent in Durham NC
Contact Person: Steed Rollins
Email: Send Email
Phone: +1 919-306-9767
Address:112 Montrose Dr.
City: Durham
State: North Carolina 27707
Country: United States
Website: http://steedrollins.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Durham, NC Real Estate Agent Drives Business Success in City\’s Rapid Growth Phase